1
|
Wang W, Hashimi B, Wang P. Targeting ferroptosis: the role of non-coding RNAs in hepatocellular carcinoma progression and therapy. NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 2025; 398:6335-6348. [PMID: 39820644 DOI: 10.1007/s00210-025-03791-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/05/2024] [Accepted: 01/06/2025] [Indexed: 01/19/2025]
Abstract
One of the most common tumors is hepatocellular carcinoma (HCC), and the prognosis for late-stage HCC is still not good. It is anticipated that improved outcomes would result from a deeper comprehension of the pathophysiology of HCC. Ferroptosis as a new discovered cell death type is linked to the progression of HCC and may be crucial for its detection, prevention, therapy, and prognosis. Numerous studies suggest that epigenetic alterations mediated by non-coding RNAs (ncRNA) might influence cancer cell susceptibility to ferroptosis. This study elucidates the processes of ferroptosis and delineates the paths by which ncRNAs influence HCC by modulating ferroptosis. Furthermore, it offers significant insights into ferroptosis-associated ncRNAs, intending to discover novel therapeutic approaches for HCC. It also explores innovative concepts for the future use of ncRNA-based ferroptosis-targeted therapeutics.
Collapse
Affiliation(s)
- Weijia Wang
- Department of Oncology, Qilu Hospital of Shandong University Dezhou Hospital (Dezhou People's Hospital), Shandong Province, China
| | - Behishta Hashimi
- Department of Midwifery, Jahan Institute of Health Sciences, Kabul, Afghanistan
| | - Ping Wang
- Department of Oncology, Yantaishan Hospital Affiliated to Binzhou Medical University, Yantai, Shandong Province, China.
| |
Collapse
|
2
|
Pahari H, Peer JA, Tripathi S, Singhvi SK, Dhir U. Downstaging of advanced hepatocellular carcinoma followed by liver transplantation using immune checkpoint inhibitors: Where do we stand? World J Gastrointest Pharmacol Ther 2024; 15:97570. [PMID: 39281264 PMCID: PMC11401018 DOI: 10.4292/wjgpt.v15.i5.97570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/02/2024] [Revised: 08/22/2024] [Accepted: 08/28/2024] [Indexed: 09/03/2024] Open
Abstract
Liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) and chronic liver disease (CLD) is limited by factors such as tumor size, number, portal venous or hepatic venous invasion and extrahepatic disease. Although previously established criteria, such as Milan or UCSF, have been relaxed globally to accommodate more potential recipients with comparable 5-year outcomes, there is still a subset of the population that has advanced HCC with or without portal vein tumor thrombosis without detectable extrahepatic spread who do not qualify or are unable to be downstaged by conventional methods and do not qualify for liver transplantation. Immune checkpoint inhibitors (ICI) such as atezolizumab, pembrolizumab, or nivolumab have given hope to this group of patients. We completed a comprehensive literature review using PubMed, Google Scholar, reference citation analysis, and CrossRef. The search utilized keywords such as 'liver transplant', 'HCC', 'hepatocellular carcinoma', 'immune checkpoint inhibitors', 'ICI', 'atezolizumab', and 'nivolumab'. Several case reports have documented successful downstaging of HCC using the atezolizumab/bevacizumab combination prior to LT, with acceptable early outcomes comparable to other criteria. Adverse effects of ICI have also been reported during the perioperative period. In such cases, a 1.5-month interval between ICI therapy and LT has been suggested. Overall, the results of downstaging using combination immunotherapy were encouraging and promising. Early reports suggested a potential ray of hope for patients with CLD and advanced HCC, especially those with multifocal HCC or branch portal venous tumor thrombosis. However, prospective studies and further experience will reveal the optimal dosage, duration, and timing prior to LT and evaluate both short- and long-term outcomes in terms of rejection, infection, recurrence rates, and survival.
Collapse
Affiliation(s)
- Hirak Pahari
- Department of Liver Transplant and Hepatobiliary Surgery, Sir Ganga Ram Hospital, New Delhi 110060, Delhi, India
| | - Javid A Peer
- Department of Surgical Gastroenterology and Liver Transplant, Sir Ganga Ram Hospital, New Delhi 110060, Delhi, India
| | - Shikhar Tripathi
- Department of Surgical Gastroenterology and Liver Transplant, Sir Ganga Ram Hospital, New Delhi 110060, Delhi, India
| | - Suresh K Singhvi
- Department of Liver Transplant and Hepatobiliary Surgery, Sir Ganga Ram Hospital, New Delhi 110060, Delhi, India
| | - Ushast Dhir
- Department of Liver Transplant and Hepatobiliary Surgery, Sir Ganga Ram Hospital, New Delhi 110060, Delhi, India
| |
Collapse
|
3
|
Ishida T, Mizumoto M, Saito T, Okumura T, Miura K, Makishima H, Iizumi T, Numajiri H, Baba K, Murakami M, Nakamura M, Nakai K, Sakurai H. Proton Beam Therapy for Treating Patients with Hepatocellular Carcinoma with Major Portal Vein Tumor Invasion: A Single Center Retrospective Study. Cancers (Basel) 2024; 16:2050. [PMID: 38893169 PMCID: PMC11171269 DOI: 10.3390/cancers16112050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2024] [Revised: 05/27/2024] [Accepted: 05/27/2024] [Indexed: 06/21/2024] Open
Abstract
Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) has a poor prognosis and is generally not indicated for surgery. Proton beam therapy (PBT) may offer an alternative treatment. In this study, long-term outcomes were examined in 116 patients (median age 66 years, 100 males) with HCC with advanced PVTT (Vp3 or Vp4) who received PBT from April 2008 to March 2018. Of these patients, 63 received PBT as definitive treatment and 53 as palliative treatment. The representative dose was 72.6 Gy (RBE) in 22 fractions. Eight patients died in follow-up, including 72 due to tumor progression. The 5-year overall survival (OS) rate was 18.0% (95% CI 9.8-26.2%) and the 5-year local control (LC) rate was 86.1% (74.9-97.3%). In multivariate analyses, performance status and treatment strategy were significantly associated with OS. The median follow-up period for survivors with definitive treatment was 33.5 (2-129) months, and the 5-year OS rate was 25.1% (12.9-37.3%) in these cases. The median survival time after definitive irradiation was >20 months. The 5-year OS rate was 9.1% (0-19.7%) for palliative irradiation. These results compare favorably with those of other therapies and suggest that PBT is a useful option for cases of HCC with advanced PVTT that cannot undergo surgery, with an expected survival benefit and good local control. Determining the optimal indication for this treatment is a future challenge.
Collapse
Affiliation(s)
- Toshiki Ishida
- Department of Radiation Oncology, University of Tsukuba Hospital, 2-1-1 Tsukuba, Ibaraki 305-8576, Japan; (T.I.); (T.S.); (T.O.); (K.M.); (H.M.); (T.I.); (H.N.); (K.B.); (M.M.); (M.N.); (K.N.); (H.S.)
| | - Masashi Mizumoto
- Department of Radiation Oncology, University of Tsukuba Hospital, 2-1-1 Tsukuba, Ibaraki 305-8576, Japan; (T.I.); (T.S.); (T.O.); (K.M.); (H.M.); (T.I.); (H.N.); (K.B.); (M.M.); (M.N.); (K.N.); (H.S.)
| | - Takashi Saito
- Department of Radiation Oncology, University of Tsukuba Hospital, 2-1-1 Tsukuba, Ibaraki 305-8576, Japan; (T.I.); (T.S.); (T.O.); (K.M.); (H.M.); (T.I.); (H.N.); (K.B.); (M.M.); (M.N.); (K.N.); (H.S.)
| | - Toshiyuki Okumura
- Department of Radiation Oncology, University of Tsukuba Hospital, 2-1-1 Tsukuba, Ibaraki 305-8576, Japan; (T.I.); (T.S.); (T.O.); (K.M.); (H.M.); (T.I.); (H.N.); (K.B.); (M.M.); (M.N.); (K.N.); (H.S.)
- Department of Radiation Oncology, Ibaraki Prefectural Central Hospital, Ibaraki 309-1703, Japan
| | - Kosei Miura
- Department of Radiation Oncology, University of Tsukuba Hospital, 2-1-1 Tsukuba, Ibaraki 305-8576, Japan; (T.I.); (T.S.); (T.O.); (K.M.); (H.M.); (T.I.); (H.N.); (K.B.); (M.M.); (M.N.); (K.N.); (H.S.)
- Department of Radiation Oncology, JCHO Tokyo Shinjuku Medical Center, Tokyo 162-8543, Japan
| | - Hirokazu Makishima
- Department of Radiation Oncology, University of Tsukuba Hospital, 2-1-1 Tsukuba, Ibaraki 305-8576, Japan; (T.I.); (T.S.); (T.O.); (K.M.); (H.M.); (T.I.); (H.N.); (K.B.); (M.M.); (M.N.); (K.N.); (H.S.)
| | - Takashi Iizumi
- Department of Radiation Oncology, University of Tsukuba Hospital, 2-1-1 Tsukuba, Ibaraki 305-8576, Japan; (T.I.); (T.S.); (T.O.); (K.M.); (H.M.); (T.I.); (H.N.); (K.B.); (M.M.); (M.N.); (K.N.); (H.S.)
| | - Haruko Numajiri
- Department of Radiation Oncology, University of Tsukuba Hospital, 2-1-1 Tsukuba, Ibaraki 305-8576, Japan; (T.I.); (T.S.); (T.O.); (K.M.); (H.M.); (T.I.); (H.N.); (K.B.); (M.M.); (M.N.); (K.N.); (H.S.)
| | - Keiichiro Baba
- Department of Radiation Oncology, University of Tsukuba Hospital, 2-1-1 Tsukuba, Ibaraki 305-8576, Japan; (T.I.); (T.S.); (T.O.); (K.M.); (H.M.); (T.I.); (H.N.); (K.B.); (M.M.); (M.N.); (K.N.); (H.S.)
| | - Motohiro Murakami
- Department of Radiation Oncology, University of Tsukuba Hospital, 2-1-1 Tsukuba, Ibaraki 305-8576, Japan; (T.I.); (T.S.); (T.O.); (K.M.); (H.M.); (T.I.); (H.N.); (K.B.); (M.M.); (M.N.); (K.N.); (H.S.)
| | - Masatoshi Nakamura
- Department of Radiation Oncology, University of Tsukuba Hospital, 2-1-1 Tsukuba, Ibaraki 305-8576, Japan; (T.I.); (T.S.); (T.O.); (K.M.); (H.M.); (T.I.); (H.N.); (K.B.); (M.M.); (M.N.); (K.N.); (H.S.)
| | - Kei Nakai
- Department of Radiation Oncology, University of Tsukuba Hospital, 2-1-1 Tsukuba, Ibaraki 305-8576, Japan; (T.I.); (T.S.); (T.O.); (K.M.); (H.M.); (T.I.); (H.N.); (K.B.); (M.M.); (M.N.); (K.N.); (H.S.)
| | - Hideyuki Sakurai
- Department of Radiation Oncology, University of Tsukuba Hospital, 2-1-1 Tsukuba, Ibaraki 305-8576, Japan; (T.I.); (T.S.); (T.O.); (K.M.); (H.M.); (T.I.); (H.N.); (K.B.); (M.M.); (M.N.); (K.N.); (H.S.)
| |
Collapse
|